United States v. GlaxoSmithKline
From Wikipedia, the free encyclopedia
United States v. GlaxoSmithKline was a case before the United States District Court for the Eastern District of Pennsylvania. Robert J. Merena was one of the first who filed claims against SmithKline Beecham Clinical Laboratories on November 12, 1993. The complaints alleged that GlaxoSmithKline, which operated a system of clinical laboratories, adopted myriad complicated procedures for the purpose of defrauding state and federal healthcare programs, in particular Medicare and Medicaid.[1] The U.S. Justice Department publicly praised Robert Merena for his "cooperation and support" in helping the government collect the largest settlement ever involving a whistle-blower lawsuit.[2] The SmithKline settlement is considered to be one of the largest whistleblower assisted recoveries in the history of the United States.[3]
United States v. GlaxoSmithKline | |
---|---|
![]() | |
Court | United States District Court for the Eastern District of Pennsylvania |
Full case name | United States of America, ex rel. Robert J. Merena, et al. v. Smithkline Beecham Clinical Laboratories, Inc. |
Decided | April 10, 1998 |
Holding | |
Settled under court order; settled for $325 million. | |
Court membership | |
Judge sitting | Donald W. VanArtsdalen |